Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of bilateral intraputaminal CERE-120 plus best medical therapy versus best medical therapy alone in idiopathic Parkinson's disease
2007-006721-27Phase 2Terminated
- Sponsor
- Ceregene
- Start
- Sep 2008
- Modality
- Recombinant Proteins and Enzymes, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Neurturin gene therapy in Parkinson's disease (PD) (2 arms), sponsored by Ceregene. Primary endpoint: Primary efficacy endpoint. Started Sep 2008; status: terminated.
02
Drugs
Neurturin gene therapy
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2007-006721-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006721-27.